Fleas and ticks are not only active in the spring and summer months but are a year-round risk for pets. Continuous flea and tick protection is essential, however, monthly treatments may leave gaps in protection, because pet owners frequently overlook the required dose and the flea lifecycle can last as long as 12 weeks.
Data From Multiple Countries Supports Product Benefits
Data from veterinarians and pet owners involving hundreds of thousands of dogs in multiple countries underlines the strong efficacy and safety profile of BRAVECTO, and makes a connection between treatment satisfaction, adherence to veterinarians’ treatment recommendations and longer-lasting pet protection.
Seven global real-world studies support the benefits of longer-lasting flea and tick protection. These studies evaluated the positive impact of extended duration flea and tick control in the U.S., U.K., Australia, Spain and South Africa, and measured the increase in adherence to veterinary recommendations that accompanies the extended duration of flea and tick control.
"These studies show that, by using a longer-acting flea and tick product, dog owners are more likely to keep their dogs protected from fleas and ticks for more months of the year, and are more likely to follow their veterinarian’s recommendation of using flea and tick product year-round," said Robert P. Lavan, DVM, MPVM, DACVPM, Director, Outcomes Research, Center for Observational and Real-World Evidence (CORE) at Merck Animal Health. "Furthermore, when compared to monthly flea and tick products, dog owners preferred BRAVECTO and reported the convenience of less-frequent dosing as a key benefit of extended duration flea and tick control." The CORE function is unique to Merck Animal Health as it involves a special group of people dedicated to real-world science and evidence focused on animal health and well-being.
In flea and tick control, pet owner adherence to treatment recommendations is critical for medication effectiveness. Studies found that dog owners using longer-lasting BRAVECTO adhered better to veterinarian flea and tick treatment recommendations, providing their dogs with more months of flea and tick protection. A cross-sectional study of 24 veterinary hospitals in the U.S., published in Parasites & Vectors, found that while almost all veterinary hospitals recommended 12 months of flea and tick prevention, only 62 percent of dog owners recalled this recommendation.ii "This study demonstrates that pet owner flea and tick treatment adherence falls short of veterinarians’ recommendations, and we have work to do to help people control these pests," said Rob Armstrong, DVM, DVSc, Director, Scientific Affairs, Merck Animal Health. "Treatments that protect for a longer period contribute to improved adherence to treatment recommendations. For example, BRAVECTO provides coverage for a year with about four doses vs. 12 doses for monthly products."
Keeping Pets Safe and Healthy
Fleas and ticks are not just a nuisance, but also pose animal and human health risks, as they can transmit diseases such as Lyme disease, Babesiosis and Bartonellosis. Since its introduction in 2014, BRAVECTO has provided longer-lasting flea and tick protection, with more than 100 million doses distributed in 85 countries and tested in over 170 clinical studies. "We continue to be honored to work with veterinarians to keep pets safe and healthy through the benefits of longer-lasting flea and tick protection," said Dr. Armstrong. "Veterinarians continue to advance the health and well-being of animals and the people who care for them."
The full studies are available here:
Please see Prescribing Information for BRAVECTO® at www.us.bravecto.com.